FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:2095 June 27, 2002 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article Related Article PubMed Citation

To the Editor: Visicol (InKine Pharmaceutical), which contains 1.5 g of sodium phosphate per tablet, is a bowel evacuant for colonoscopy that was approved by the Food and Drug Administration (FDA) in September 2000. Its proposed mechanism of action is an osmotic effect. Twenty tablets are taken the evening before the colonoscopy (three tablets with at least 8 oz of clear liquids every 15 minutes [the last dose being two tablets]) and again the next morning.¹ From April to July 2001, four reports of tonic–clonic seizure associated with the administration of Visicol were received by the FDA MedWatch system (. . . [Full Text of this Article]

Related Letters:

Reversible Chorea and Focal Dystonia in Vitamin B₁₂ Deficiency
Pacchetti C., Cristina S., Nappi G.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:295, Jul 25, 2002. Correspondence

Seizure Associated with Use of Visicol for Colonoscopy
Rose M., Jacob L. S.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:295-296, Jul 25, 2002. Correspondence

This article has been cited by other articles:

• Rose, M., Karlstadt, R. G., Walker, K. (2005). Renal failure following bowel cleansing with a sodium phosphate purgative. Nephrol Dial Transplant 20: 1518-1519 [Full Text]  
• Rose, M., Jacob, L. S. (2002). Seizure Associated with Use of Visicol for Colonoscopy. NEJM 347: 295-296 [Full Text]